In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

US House Drug Pricing Bill Amended To Target Launch Prices, Set For Swift Advance

House Speaker Pelosi’s amended HR 3 expands scope of targeted drugs, adds manufacturer transparency requirements ahead of dual markups and a hearing on 17 October.

Pricing Debate Legislation

PhRMA Willing To Contribute To Drug ‘Affordability’ – But Mum On How Much

PhRMA CEO Steven Ubl offers list of policy alternatives to drug pricing bills pending in the US Congress that he argues would stifle innovation; industry's plans, on the other hand, could produce "meaningful" legislation.

Pricing Debate Pricing Strategies

Beyond ICER: Arnold Foundation Wants To Dig Deeper On R&D And Pricing

Arnold Foundation VP Mark Miller explains how research into “what it costs to bring a drug to market” could supplement existing efforts to determine how prescription drug prices line up with value.

Cost Effectiveness Pricing Debate

HHS Safe Harbor For Value-Based Drug Contracts May Be On Horizon

US proposed rule establishing new safe harbors from anti-kickback rules for value-based and outcomes-based contracts limits protections to clinicians, providers and certain other groups and expressly excludes pharmaceutical manufacturers. But HHS suggests a separate safe harbor for prescription drug contracts may be forthcoming.
Reimbursement Pricing Strategies

Drugs With ‘Unsupported Price Increases’ Add $5bn To US Spending – ICER

Pharmaceutical Research and Manufacturers of America describes report as “flawed” and designed to advance the “false narrative that spending on medicines in increasing.”

Pricing Debate Pricing Strategies

Drugs With ‘Unsupported Price Increases’ Add $5bn To US Spending – ICER

Pharmaceutical Research and Manufacturers of America describes report as “flawed” and designed to advance the “false narrative that spending on medicines in increasing.”

Pricing Debate Policy
See All
Advertisement
UsernamePublicRestriction

Register